Suppr超能文献

西地那非对2型糖尿病合并勃起功能障碍男性患者的疗效与安全性

[Efficacy and safety of sildenafil in men with type 2 diabetes mellitus and erectile dysfunction].

作者信息

Escobar-Jiménez Fernando

机构信息

Servicio de Endocrinología, Hospital Universitario San Cecilio. Granada, España.

出版信息

Med Clin (Barc). 2002 Jun 29;119(4):121-4. doi: 10.1016/s0025-7753(02)73339-3.

Abstract

BACKGROUND

Erectile dysfunction is a common complication in patients with diabetes mellitus, which impairs quality of life, decreases self-esteem and can affect partners relationships. Sildenafil improves nitric oxide-dependent relaxation of smooth muscle in corpora cavernosa--induced by an increase in cGMP via inhibition of phosphodiesterase 5.

PATIENTS AND METHOD

Multicenter, randomized, double-blind, placebo-controlled study with flexible doses of sildenafil. The study was performed in 16 centers and recruited a total of 112 subjects with diabetes mellitus who had erectile dysfunction. At the start and end of the study, the following questionnaires were administered: International Index of Erectile Function (IIEF), Global Efficacy Assessment Question and Quality of Life Questionnaire (Fugl-Meyer). Of the 112 initially recruited patients, 92 received treatment, sildenafil in 44 and placebo in 48.

RESULTS

A clear improvement was observed in the capacity to achieve and maintain an erection; 55.3% diabetic patients receiving sildenafil had at least one successful sexual intercourse (15.6% in the placebo group). In addition, significant improvements were seen in other aspects of the sexual activity of treated subjects. Among those treated with sildenafil, 46.3% reported a clear improvement of erections as compared to their baseline conditions (i.e, prior to treatment) vs only 14.9% in the placebo group. The percentage of a successful intercourse clearly increased, from 6 to 49%. Sildenafil was well-tolerated. Side effects were mild and transient.

CONCLUSIONS

Sildenafil is an effective, safe treatment for erectile dysfunction in diabetic patients.

摘要

背景

勃起功能障碍是糖尿病患者常见的并发症,会损害生活质量、降低自尊并可能影响伴侣关系。西地那非可改善阴茎海绵体内一氧化氮依赖的平滑肌舒张,这是通过抑制磷酸二酯酶5增加环磷酸鸟苷(cGMP)来实现的。

患者与方法

一项多中心、随机、双盲、安慰剂对照研究,使用灵活剂量的西地那非。该研究在16个中心进行,共招募了112名患有勃起功能障碍的糖尿病患者。在研究开始和结束时,发放了以下问卷:国际勃起功能指数(IIEF)、总体疗效评估问卷和生活质量问卷(Fugl-Meyer)。在最初招募的112名患者中,92名接受了治疗,44名服用西地那非,48名服用安慰剂。

结果

在勃起能力和维持勃起方面观察到明显改善;接受西地那非治疗的糖尿病患者中有55.3%至少有一次性交成功(安慰剂组为15.6%)。此外,治疗组患者在性活动的其他方面也有显著改善。在服用西地那非的患者中,46.3%报告勃起情况较基线状态(即治疗前)有明显改善,而安慰剂组仅为14.9%。成功性交的比例明显增加,从6%增至49%。西地那非耐受性良好。副作用轻微且短暂。

结论

西地那非是治疗糖尿病患者勃起功能障碍的一种有效、安全的药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验